BMS deploys Schrödinger's Bunsen AI platform for drug discovery

Bristol Myers Squibb's deployment of Bunsen represents a deepening commitment to AI-native drug discovery infrastructure that extends beyond standard enterprise software licensing. The November 2020 relationship—which involved substantial upfront capital and significant milestone payments (USD 55 million upfront, up to USD 2.7 billion in milestones)—demonstrated BMS's confidence in Schrödinger's physics-based computational approach. This new agreement shifts the relationship from purely transactional to collaborative, with BMS scientists co-developing new Bunsen capabilities alongside the platform deployment. This model reflects a broader trend in pharma AI partnerships where large enterprises are moving from vendor-consumer relationships toward joint innovation structures.

The timing of this expansion aligns with BMS's wider AI infrastructure buildout. In July 2026, BMS expanded its NVIDIA compute capacity, and in May 2026 deployed Anthropic's Claude across global operations. Bunsen's autonomous execution of multi-step molecular workflows—from planning through interpretation—complements these investments by creating a specialized, physics-informed layer atop general-purpose compute and reasoning capabilities. Schrödinger's Q2 2026 annual contract value of USD 29.6 million, up 27% year-over-year, with Bunsen's early access launch cited as an operational highlight, suggests the agentic platform is a material contributor to recent growth, though the broader BMS agreement's financial impact remains undisclosed.